Navigation Links
Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
Date:7/19/2012

to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2011.  Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Regeneron Forward-Looking Statements

This news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron, and actual events or results may differ materially from these forward-looking statements.  These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's products and product candidates and research and clinical programs now underway or planned, including without limitation SAR236553/REGN727, unforeseen safety issues resulting from the administration of products and product candidates in patients, the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates, determinations by regulatory and administrativ
'/>"/>

SOURCE Sanofi and Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Sanofi Signs Agreement for Type 1 Diabetes Research with Boston Academic Teaching Hospital
2. Collaboration between Sanofi and Joslin Diabetes Center to focus on new drugs for diabetes
3. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
4. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
5. PharmaVentures Client Sanofi Wins Scrip Outsourcing Deal of the Year Award
6. Regeneron Announces March 2012 Investor Conference Presentations
7. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
8. Elsevier Launches International Journal for Parasitology: Parasites and Wildlife
9. Elsevier Launches a New Product Literature Database Solution for Life Science Professionals
10. GenoSpace Announces the Launch of a Cloud-Based "Information Ecosystem" for Advancing 21st-Century Personalized Medicine
11. infirst HEALTHCARE Established to Launch Novel Consumer Medicines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... September 17, 2014 Shimadzu ... Liquid Chromatograph (2D-LC), which offers a powerful ... matrices. The system provides a new level ... which is beneficial to scientists analyzing pharmaceutical ... natural products. , Comprehensive 2D-LC combines two ...
(Date:9/17/2014)... September 17, 2014 Immunomic Therapeutics, Inc. ... Research (SBIR) grant to support the continued preclinical development ... ITI with approximately $255,000 over one year to conduct ... of food allergy, affect over one million Americans and ... allergy. Tree nut exposure is also a risk for ...
(Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire/ - SQI Diagnostics ... that develops and commercializes proprietary technologies and products for ... have been approved for trading in the ... Trading is expected to commence on September 17, 2014 ... will continue to trade on the TSX Venture Exchange ...
(Date:9/17/2014)... Angeles, CA (PRWEB) September 17, 2014 Escape ... microchip for pets which will alert owners if their pet ... using GPS from an implanted microchip in the pet’s body. ... implantable microchips for pets have been around for many years, ... and are not able to track a pet’s location or alert ...
Breaking Biology Technology:Shimadzu’s New Nexera-e Two Dimensional Comprehensive Liquid Chromatograph Empowers Laboratories to Separate Even the Most Complex Mixtures 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3Implantable Microchip for Pets with GPS Tracking - Patent Filed by Escape Alert, LLC. 2Implantable Microchip for Pets with GPS Tracking - Patent Filed by Escape Alert, LLC. 3
... CROSSE, Wis., Dec. 8, 2011  Prem Rabindranauth, MD, a heart ... in La Crosse, Wis., is using an exciting ... perform heart bypass surgery. To perform MICS, a very small ... cut through the breast bone that is needed with traditional ...
... WaferGen Biosystems, Inc. (OTCBB:WGBS), an emerging genomic analysis ... its corporate presentation at the Oppenheimer 22nd Annual Healthcare ... 2011. The Company is scheduled to present ... Time.  The presentation will be webcast live and will ...
... Therapies, Inc. (OTCQB: BRTX) ("BRT") today announced that it ... University of Utah.  Pursuant to the agreement, the University ... derived from stem cells. The agreement ... strategic collaboration between BRT and the University of Utah, ...
Cached Biology Technology:Gundersen Lutheran Offers Heart Surgery with Less Pain, Faster Recovery 2WaferGen to Present Corporate Overview at Oppenheimer Healthcare Conference 2BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah 2
(Date:9/17/2014)... Evolution and Yale University offers compelling support for the ... partially predict the likelihood of being diagnosed with mental ... life. The study analyzed medical records of 1.75 million ... 30 years, and adjusted for almost all other known ... Proceedings of the Royal Society, London B . ...
(Date:9/17/2014)... at the Catalan Institute of Oncology-Bellvitge Biomedical Research ... 5 genes differentially expressed in normal accompanying cells ... be used to classify colorectal tumors, predict the ... clinical decisions to prevent relapses. , Biomarkers ... common in our population considering both sexes. About ...
(Date:9/17/2014)... on a Carnegie expedition in Australia,s Great Barrier Reef ... since the mid-1970s. The scientists suggest that ocean acidification ... slowdown. , In a quest for historical context ... current measurements of the growth rate of a section ... more than 30 years ago. Their work is published ...
Breaking Biology News(10 mins):Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Five genes to predict colorectal cancer relapses 2Coral growth rate plummets in 30-year comparison 2
... clinical trial to test a revolutionary treatment for blindness ... (University College London). The trial, funded by the Department ... could have a significant impact on future treatments for ... and children who have a condition called Leber’s congenital ...
... are an integral part of African culture, one of ... South Africa, 21st century drug therapy is used side-by-side ... plants have been used in African medicine to treat ... of the purported benefits of many plants is still ...
... brain study, even people who seemed resilient but were close to ... 11, 2001, have brains that are more reactive to emotional stimuli ... is the finding of a new Cornell study that excluded people ... (PTSD) or major depression. One of the first studies to look ...
Cached Biology News:First clinical trial of gene therapy for childhood blindness 28 plants from South Africa may hold potential for treating high blood pressure 28 plants from South Africa may hold potential for treating high blood pressure 38 plants from South Africa may hold potential for treating high blood pressure 4Traumas like Sept. 11 make brains more reactive to fear 2
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
... Abpromise for all tested applications). ... to KLH derived from within residues 400 ... acid sequence is proprietary)(Peptide available as ... ID: 55693 Swiss ...
Perm/Wash Buffer 250 Tests...
Mouse monoclonal to OCIL ( Abpromise for all tested applications)....
Biology Products: